Literature DB >> 31165369

Efavirenz is associated with altered fronto-striatal function in HIV+ adolescents.

Stéfan Du Plessis1, Alexander Perez2, Jean-Paul Fouche3, Nicole Phillips3, John A Joska3, Matthijs Vink4, Landon Myer2,5, Heather J Zar6,7, Dan J Stein3,8, Jacqueline Hoare3.   

Abstract

Neurotoxicity associated with the antiretroviral efavirenz (EFV) has been documented in HIV-infected adults, but there are no data on the impact of EFV on brain function in adolescents. We investigated potential alterations in fronto-striatal function associated with EFV use in adolescents. A total of 86 adolescents underwent a Stop Signal Anticipation Task (SSAT) during functional MRI (fMRI), 39 HIV+ adolescents receiving EFV, 27 HIV+ adolescents on antiretroviral therapy without EFV (matched on age, gender, education, CD4 cell count and HIV viral load) and 20 HIV- matched controls (matched on age and gender). The task required participants to give timed GO responses with occasional STOP signals at fixed probabilities. Reactive inhibition was modelled as a correct STOP response and proactive inhibition was modelled after response slowing as the STOP probability increases. A priori mask-based regions associated with reactive and proactive inhibition were entered into two respective multivariate ANOVAs. The EFV treatment group showed significantly blunted proactive inhibitory behavioural responses compared to HIV+ adolescents not receiving EFV. There was no difference in reactive inhibition between treatment groups. We also demonstrated a significant effect of EFV treatment on BOLD signal in proactive inhibition regions. There was no difference in regions involved in reactive inhibition. We found no differences between adolescents not receiving EFV and HIV- controls, showing that functional and behavioural differences were unique to the EFV group. Here, we demonstrate for the first time a potential adverse impact of EFV on higher cortical function in young HIV+ adolescents.

Entities:  

Keywords:  Adolescence; Efavirenz; HIV; fMRI

Year:  2019        PMID: 31165369      PMCID: PMC6891144          DOI: 10.1007/s13365-019-00764-9

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  27 in total

1.  Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients.

Authors:  T Ernst; L Chang; J Jovicich; N Ames; S Arnold
Journal:  Neurology       Date:  2002-11-12       Impact factor: 9.910

Review 2.  Neuronal toxicity of efavirenz: a systematic review.

Authors:  Eric H Decloedt; Gary Maartens
Journal:  Expert Opin Drug Saf       Date:  2013-07-29       Impact factor: 4.250

3.  Structural brain changes in perinatally HIV-infected young adolescents in South Africa.

Authors:  Jacqueline Hoare; Jean-Paul Fouche; Nicole Phillips; John A Joska; Landon Myer; Heather J Zar; Dan J Stein
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

4.  Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells.

Authors:  Ana Blas-García; Nadezda Apostolova; Daniel Ballesteros; Daniel Monleón; Jose M Morales; Milagros Rocha; Victor M Victor; Juan V Esplugues
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

5.  Neuronal bioenergetics and acute mitochondrial dysfunction: a clue to understanding the central nervous system side effects of efavirenz.

Authors:  Haryes A Funes; Nadezda Apostolova; Fernando Alegre; Ana Blas-Garcia; Angeles Alvarez; Miguel Marti-Cabrera; Juan V Esplugues
Journal:  J Infect Dis       Date:  2014-05-09       Impact factor: 5.226

6.  Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the Anti-Retroviral Drug Efavirenz and its Primary Metabolite 8-Hydroxy Efavirenz.

Authors:  Christian Arend; Alica Rother; Stefan Stolte; Ralf Dringen
Journal:  Neurochem Res       Date:  2016-09-21       Impact factor: 3.996

7.  Applying the HIV-associated neurocognitive disorder diagnostic criteria to HIV-infected youth.

Authors:  Jacqueline Hoare; Nicole Phillips; John A Joska; Robert Paul; Kirsten A Donald; Dan J Stein; Kevin G F Thomas
Journal:  Neurology       Date:  2016-05-20       Impact factor: 9.910

8.  Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

Authors:  Luis B Tovar-y-Romo; Namandjé N Bumpus; Daniel Pomerantz; Lindsay B Avery; Ned Sacktor; Justin C McArthur; Norman J Haughey
Journal:  J Pharmacol Exp Ther       Date:  2012-09-13       Impact factor: 4.030

9.  On the ability to inhibit thought and action: general and special theories of an act of control.

Authors:  Gordon D Logan; Trisha Van Zandt; Frederick Verbruggen; Eric-Jan Wagenmakers
Journal:  Psychol Rev       Date:  2014-01       Impact factor: 8.934

10.  Does efavirenz replacement improve neurological function in treated HIV infection?

Authors:  B Payne; T J Chadwick; A Blamire; K N Anderson; J Parikh; J Qian; A M Hynes; J Wilkinson; D A Price
Journal:  HIV Med       Date:  2017-03-01       Impact factor: 3.180

View more
  2 in total

1.  Longitudinal Effects of Combination Antiretroviral Therapy on Cognition and Neuroimaging Biomarkers in Treatment-Naive People With HIV.

Authors:  Miriam T Weber; Alan Finkelstein; Md Nasir Uddin; Elizabeth Asiago Reddy; Roberto C Arduino; Lu Wang; Madalina E Tivarus; Jianhui Zhong; Xing Qiu; Giovanni Schifitto
Journal:  Neurology       Date:  2022-06-22       Impact factor: 11.800

2.  Effects of perinatal HIV-infection on the cortical thickness and subcortical gray matter volumes in young adulthood.

Authors:  Beatriz Ruiz-Saez; Manuela Martín-Bejarano García; Ana Martinez de Aragon; Mario Gil-Correa; Helena Melero; Norberto Antonio Malpica; Santiago Jimenez de Ory; Berta Zamora; Sara Guillen; Pablo Rojo; Lola Falcon-Neyra; Alberto Alvarez; Pilar Fernandez; María Luisa Lorente-Jareño; Jose Tomas Ramos; Talía Sainz; Carlos Velo; Maria Luisa Navarro; Maria Isabel Gonzalez-Tomé
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.